AbbVie’s Skyrizi helps more Crohn's patients stay off steroids than J&J’s Stelara, PhIII data show
16 Oct 2023
Phase 3Drug ApprovalClinical ResultBiosimilar
AbbVie’s Skyrizi has demonstrated significantly higher rates of steroid-free clinical and endoscopic remission versus rival Johnson & Johnson’s Stelara in a Phase III trial, helping set the Crohn’s disease drug apart in an increasingly competitive market.
Stelara won an FDA approval for Crohn’s disease in 2016, while Skyrizi was approved three years later in 2019. But the competition is heating up with Stelara biosimilars set to enter the market in 2025, government price negotiations in 2026, and a new rival emerging in the form of Pfizer’s oral S1P inhibitor VelsipityS1P inhibitor Velsipity for ulcerative colitis.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.